Osimertinib in Combination with Bevacizumab Fails in Advanced Lung Adenocarcinoma Harboring EGFR T790M

Documenti analoghi

• Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR
  di: Sakai, Hitomi, et al.
  Pubblicazione: (2017)
• Case report: primary resistance to osimertinib in erlotinib-pretreated lung adenocarcinoma with EGFR T790 M mutation
  di: Zheng, Lin-Peng, et al.
  Pubblicazione: (2018)
• Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report
  di: Zhao, Jing, et al.
  Pubblicazione: (2018)
• Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
  di: Mok, T.S., et al.
  Pubblicazione: (2016)
• The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma
  di: Zhang, Qiuyi, et al.
  Pubblicazione: (2016)